<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02642965</url>
  </required_header>
  <id_info>
    <org_study_id>AAML1421</org_study_id>
    <secondary_id>NCI-2015-01917</secondary_id>
    <secondary_id>PAAML1421_R02PAPP01</secondary_id>
    <secondary_id>AAML1421</secondary_id>
    <secondary_id>AAML1421</secondary_id>
    <secondary_id>U10CA180886</secondary_id>
    <nct_id>NCT02642965</nct_id>
  </id_info>
  <brief_title>Liposomal Cytarabine-Daunorubicin CPX-351, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children With Relapsed Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the side effects and best dose of liposomal
      cytarabine-daunorubicin CPX-351 (CPX-351) when given with fludarabine phosphate, cytarabine,
      and filgrastim and to see how well they work in treating younger patients with acute myeloid
      leukemia that has come back after treatment (relapsed) or is not responding to treatment (is
      refractory). Liposomal cytarabine-daunorubicin CPX-351 is made up of two chemotherapy drugs,
      cytarabine and daunorubicin hydrochloride, and works to stop cancer cell growth by blocking
      the cells from dividing. Drugs used in chemotherapy, such as fludarabine phosphate and
      cytarabine, work in different ways to stop the growth of cancer cells, either by killing the
      cells, by stopping them from dividing, or by stopping them from spreading. Filgrastim may
      increase the production of blood cells and may help the immune system recover from the side
      effects of chemotherapy. Giving liposomal cytarabine-daunorubicin CPX-351 followed by
      fludarabine phosphate, cytarabine, and filgrastim may be a better treatment for patients with
      relapsed acute myeloid leukemia and may cause fewer side effects to the heart, a common
      effect of other chemotherapy treatments for acute myeloid leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine a recommended phase 2 dose (RP2D) and the toxicities associated with CPX-351
      in pediatric and young adult patients with relapsed/refractory acute myeloid leukemia (AML).
      The phase 1 portion of the study has been completed as of 12/12/2016 and dose level #1 (135
      Units/m2/dose) was found to be the recommended phase 2 dose.

      II. To estimate the response rate (complete remission [CR] plus complete remission with
      partial platelet recovery [CRp]) after CPX-351 (cycle 1) followed by fludarabine phosphate,
      cytarabine, and filgrastim (FLAG) (cycle 2) in children with AML in first relapse.

      SECONDARY OBJECTIVES:

      I. To estimate the response rate (CR + CRp + complete remission with incomplete blood count
      recovery [CRi]) after one cycle of CPX-351.

      II. To describe the pharmacokinetics of plasma cytarabine and daunorubicin after CPX-351
      administration to pediatric and young adult patients with relapsed/refractory AML.

      TERTIARY OBJECTIVES:

      I. To describe the response in biomarkers of cardiac injury to a single cycle of CPX-351.

      II. To explore the effect of CPX-351 on novel biochemical and imaging markers of
      cardiotoxicity, including plasma micro ribonucleic acid (RNAs) (miRNA) and myocardial
      deformation.

      III. To explore the role of rare coding variants as risk factors for anthracycline-induced
      cardiomyopathy.

      OUTLINE:

      COURSE 1: Patients receive cytarabine intrathecally (IT) on day 0 and at day 28-30 or up to 1
      week prior to day 1 of course 2, and liposomal cytarabine-daunorubicin CPX-351 intravenously
      (IV) over 90 minutes on days 1, 3, and 5. Patients without evidence of central nervous system
      (CNS) disease (CNS1) receive no further CNS-directed therapy in course 1. Patients with &lt; 5
      white blood cells per microliter of blood with blast cells (CNS2) disease may receive an
      additional dose of cytarabine IT on day 7 at the discretion of the investigator. Patients
      meeting criteria for CR, CRp, and CRi may proceed to course 2.

      COURSE 2: Beginning 28 days later, patients receive filgrastim subcutaneously (SC) on days
      1-5 and then on day 15 until blood count recovery, and fludarabine phosphate IV over 30
      minutes and high-dose cytarabine IV over 1-3 hours on days 1-5.

      After completion of study treatment, patients are followed up periodically for 12 months, and
      then yearly for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events associated with liposomal cytarabine-daunorubicin CPX-351, graded according to NCI CTCAE version 4.0</measure>
    <time_frame>Up to 12 months post-treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate (CR or CRp) using the revised AML International Working Group Criteria</measure>
    <time_frame>Up to 8 weeks (after up to 2 courses)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>RP2D determined by incidence of dose-limiting toxicity, graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liposomal cytarabine-daunorubicin CPX-351 area under the curve (AUC)</measure>
    <time_frame>Baseline (prior to infusion); 45 minutes; 90 minutes; 2, 5, 8, and 12 hours on day 5; 24 hours post-infusion day 6; 72 hours post infusion day 8; and 120 hours post infusion on day 10 of course 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liposomal cytarabine-daunorubicin CPX-351 clearance (CL)</measure>
    <time_frame>Baseline (prior to infusion); 45 minutes; 90 minutes; 2, 5, 8, and 12 hours on day 5; 24 hours post-infusion day 6; 72 hours post infusion day 8; and 120 hours post infusion on day 10 of course 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liposomal cytarabine-daunorubicin CPX-351 time to maximum concentration (Tmax) 1/2</measure>
    <time_frame>Baseline (prior to infusion); 45 minutes; 90 minutes; 2, 5, 8, and 12 hours on day 5; 24 hours post-infusion day 6; 72 hours post infusion day 8; and 120 hours post infusion on day 10 of course 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liposomal cytarabine-daunorubicin CPX-351 volume of distribution (Vd)</measure>
    <time_frame>Baseline (prior to infusion); 45 minutes; 90 minutes; 2, 5, 8, and 12 hours on day 5; 24 hours post-infusion day 6; 72 hours post infusion day 8; and 120 hours post infusion on day 10 of course 1</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in GLS</measure>
    <time_frame>Baseline to up to 28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in high sensitive c-reactive protein (HS-CRP) levels</measure>
    <time_frame>Baseline to up to day 30</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in miRNA using TaqMan microRNA Assays</measure>
    <time_frame>Baseline to up to day 30</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in N-terminal pro b-type natriuretic peptide (NT-BNP) levels</measure>
    <time_frame>Baseline to up to day 30</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in troponin levels</measure>
    <time_frame>Baseline to up to day 30</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Length of hospitalization time</measure>
    <time_frame>Up to 1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to bone marrow count recovery</measure>
    <time_frame>Up to 1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to peripheral blood cell count recovery</measure>
    <time_frame>Up to 1 year</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Recurrent Childhood Acute Myeloid Leukemia</condition>
  <condition>Secondary Acute Myeloid Leukemia</condition>
  <condition>Therapy-Related Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (CPX-351 and FLAG)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COURSE 1: Patients receive cytarabine IT on day 0 and at day 28-30 or up to 1 week prior to day 1 of course 2, and liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5. Patients with CNS1 receive no further CNS-directed therapy in course 1. Patients with CNS2 disease may receive an additional dose of cytarabine IT on day 7 at the discretion of the investigator. Patients meeting criteria for CR, CRp, and CRi may proceed to course 2.
COURSE 2: Beginning 28 days later, patients receive filgrastim SC on days 1-5 and then on day 15 until blood count recovery, and fludarabine phosphate IV over 30 minutes and high-dose cytarabine IV over 1-3 hours on days 1-5.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IT or IV</description>
    <arm_group_label>Treatment (CPX-351 and FLAG)</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-Cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosar-U</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Given SC or IV</description>
    <arm_group_label>Treatment (CPX-351 and FLAG)</arm_group_label>
    <other_name>Filgrastim XM02</other_name>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
    <other_name>r-metHuG-CSF</other_name>
    <other_name>Recombinant Methionyl Human Granulocyte Colony Stimulating Factor</other_name>
    <other_name>rG-CSF</other_name>
    <other_name>Tbo-filgrastim</other_name>
    <other_name>Tevagrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (CPX-351 and FLAG)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>Oforta</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (CPX-351 and FLAG)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Cytarabine-Daunorubicin CPX-351</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (CPX-351 and FLAG)</arm_group_label>
    <other_name>CPX-351</other_name>
    <other_name>Cytarabine-Daunorubicin Liposome for Injection</other_name>
    <other_name>Liposomal AraC-Daunorubicin CPX-351</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (CPX-351 and FLAG)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have had histologic verification of AML at original diagnosis;

          -  Patient must have one of the following:

               1. Recurrent disease with &gt;= 5% blasts in the bone marrow (M2/M3 bone marrow), with
                  or without extramedullary disease

               2. Recurrent disease with an absolute blast count greater than 1,000 per microliter
                  in the peripheral blood with or without extramedullary disease

          -  To be eligible for the dose-finding phase:(The Dose-Finding Phase completed in
             12/2016)

               -  Relapsed patients

                    -  Patients must be in first relapse, and

                    -  Patients must not have received prior re-induction therapy

               -  Refractory patients

                    -  Patients must not have received more than one attempt at remission
                       induction, which may consist of up to two different therapy courses;
                       Children Oncology Group (COG) AAML1031 de novo therapy including induction I
                       and induction II is an example

               -  Treatment-related AML (t-AML)

                    -  Patients must be previously untreated for secondary AML

          -  To be eligible for the Phase 2 efficacy phase:

               -  Relapsed patients:

                    -  Patients must be in first marrow relapse, and

                    -  Patients must not have received prior re-induction therapy. Donor lymphocyte
                       infusion (DLI) is considered a re-induction attempt.

          -  Patients must have the status of CNS1 or CNS2 only, and no clinical signs or
             neurologic symptoms suggestive of CNS leukemia, such as cranial palsy

          -  Patients must have a performance status corresponding to an Eastern Cooperative
             Oncology Group (ECOG) scores of 0, 1 or 2; use Karnofsky for patients &gt; 16 years of
             age and Lansky for patients =&lt; 16 years of age; Note: patients who are unable to walk
             because of paralysis, but who are up in a wheelchair, will be considered ambulatory
             for the purpose of assessing the performance score

          -  Patients must have recovered from the acute toxic effects of all prior chemotherapy,
             immunotherapy, stem cell transplant or radiotherapy prior to entering this study; all
             prior treatment-related toxicities must have resolved to =&lt; grade 2 prior to
             enrollment

          -  Myelosuppressive chemotherapy: must not have received myelosuppressive chemotherapy
             within 3 weeks of entry onto this study (excluding hydroxyurea)

               -  Cytoreduction with hydroxyurea can be initiated and continued for up to 24 hours
                  prior to the start of CPX-351

          -  Biologic (anti-neoplastic agent): at least 7 days since the completion of therapy with
             a biologic agent such as steroids, retinoids; Note: for agents that have known adverse
             events occurring beyond 7 days after administration (i.e. monoclonal antibodies), this
             period must be extended beyond the time during which acute adverse events are known to
             occur

          -  Radiation therapy (RT): &gt;= 2 weeks for local palliative RT (small port); &gt;= 6 months
             must have elapsed if prior craniospinal RT or if &gt;= 50% radiation of pelvis; &gt;= 6
             weeks must have elapsed if other substantial bone marrow (BM) radiation; Note:
             patients must have received =&lt; than 13.6 Gray (Gy) prior radiation to the mediastinum

          -  Stem cell transplant (SCT): no evidence of active graft vs. host disease for at least
             4 weeks; for allogeneic SCT patients, &gt;= 3 months must have elapsed since transplant

               -  Must have received no more than 1 prior autologous or allogeneic stem cell
                  transplant.

               -  Patients must be off all systemic immunosuppressive therapy for at least 2 weeks,
                  excluding hydrocortisone for physiologic cortisol replacement

          -  Intrathecal cytotoxic therapy:

               -  No waiting period is required for patients having received intrathecal
                  cytarabine, methotrexate, and/or hydrocortisone

               -  At least 14 days must have elapsed since receiving liposomal cytarabine
                  (DepoCyte) by intrathecal injection

          -  Growth factors:

               -  Patients must not have received growth factors for 7 days prior to CPX-351

               -  Patients must not have received pegfilgrastim for 14 days prior to CPX-351

          -  Creatinine clearance or radioisotope glomerular filtration rate (GFR) &gt;= 70
             mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows:

               -  Age 1 to &lt; 2 years: maximum serum creatinine 0.6 mg/dL (males and females)

               -  Age 2 to &lt; 6 years: maximum serum creatinine 0.8 mg/dL (males and females)

               -  Age 6 to &lt; 10 years: maximum serum creatinine 1.0 mg/dL (males and females)

               -  Age 10 to &lt; 13 years: maximum serum creatinine 1.2 mg/dL (males and females)

               -  Age 13 to &lt; 16 years: maximum serum creatinine 1.5 mg/dL (males) and 1.4 mg/dL
                  (females)

               -  Age &gt;= 16 years: maximum serum creatinine 1.7 mg/dL (males) and 1.4 mg/dL
                  (females)

          -  Direct bilirubin &lt; 1.5 x upper limit of normal (ULN) for age and institution

          -  Serum glutamate pyruvate (SGPT) (alanine aminotransferase [ALT]) =&lt; 3.0 x upper limit
             of normal (ULN) for age and institution (unless it is related to leukemic involvement)

          -  Shortening fraction of &gt;= 27% by echocardiogram, or

          -  Ejection fraction of &gt;= 50% by radionuclide angiogram or echocardiogram

          -  Corrected QT (using Bazett's formula [QTcB]) interval &lt; 500 msecs

          -  Patients with seizure disorder may be enrolled if on anticonvulsants and if seizures
             are well controlled

          -  Central nervous system (CNS) toxicity =&lt; grade 2

          -  Patients with a known history of human immunodeficiency virus (HIV) are eligible, if
             they meet all of the following conditions:

               -  No history of HIV complications with the exception of cluster of differentiation
                  (CD)4 count &lt; 200 cells/mm^3

               -  No antiretroviral therapy with overlapping toxicity such as myelosuppression

               -  HIV viral loads below the limit of detection

               -  No history of highly active antiretroviral therapy (HAART)-resistant HIV

          -  All patients and/or their parents or legal guardians must sign a written informed
             consent

        Exclusion Criteria:

          -  Patients who have received &gt; 450 mg/m^2 daunorubicin equivalents; patients who relapse
             after receiving AAML0531/AAML1031 therapy will be eligible for this study, provided
             they have not received any additional anthracyclines; NOTE: for the purposes of
             determining eligibility for this protocol, the following cardiotoxicity multipliers
             will be used to determine daunorubicin equivalents:

               -  Doxorubicin (doxorubicin hydrochloride): 1

               -  Mitoxantrone: 3

               -  Idarubicin: 3

               -  Epirubicin: 0.5

          -  Patients who are currently receiving another investigational drug

          -  Patients receiving medications for treatment of left ventricular systolic dysfunction

          -  Patients with any of the following diagnoses:

               -  Acute promyelocytic leukemia (APL)

               -  Down syndrome

               -  Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone
                  marrow failure syndrome

               -  Wilson's disease and any other disorder of copper metabolism

               -  Juvenile myelomonocytic leukemia (JMML)

          -  Patients with documented active, uncontrolled infection at the time of study entry

          -  Patients with known active hepatitis B virus (HBV) and hepatitis C virus (HCV)
             infections

          -  Patients with prior allergy to daunorubicin and/or cytarabine

          -  Female patients who are pregnant are ineligible

          -  Lactating females are not eligible

          -  Female patients of childbearing potential are not eligible unless a negative pregnancy
             test result has been obtained

          -  Sexually active patients of reproductive potential are not eligible unless they have
             agreed to use an effective contraceptive method for the duration of their study
             participation and for 30 days after the last dose of chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd Cooper</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew A. Kutny</last_name>
      <phone>205-934-0309</phone>
    </contact>
    <investigator>
      <last_name>Matthew A. Kutny</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elyssa M. Rubin</last_name>
      <phone>714-997-3000</phone>
    </contact>
    <investigator>
      <last_name>Elyssa M. Rubin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center-Mission Bay</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer R. Willert</last_name>
      <phone>877-827-3222</phone>
    </contact>
    <investigator>
      <last_name>Jennifer R. Willert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret E. Macy</last_name>
      <phone>720-777-6672</phone>
    </contact>
    <investigator>
      <last_name>Margaret E. Macy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alfred I duPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta - Egleston</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melinda G. Pauly</last_name>
      <email>helpdesk@childrensoncologygroup.org</email>
    </contact>
    <investigator>
      <last_name>Melinda G. Pauly</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospital-Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nobuko Hijiya</last_name>
      <phone>773-880-4562</phone>
    </contact>
    <investigator>
      <last_name>Nobuko Hijiya</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James M. Croop</last_name>
      <phone>800-248-1199</phone>
    </contact>
    <investigator>
      <last_name>James M. Croop</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Hospital and Health Care Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bassem I. Razzouk</last_name>
      <phone>317-338-2194</phone>
      <email>research@stvincent.org</email>
    </contact>
    <investigator>
      <last_name>Bassem I. Razzouk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>University of Minnesota/Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter M. Gordon</last_name>
      <phone>612-624-2620</phone>
    </contact>
    <investigator>
      <last_name>Peter M. Gordon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carola A. Arndt</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Carola A. Arndt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>The Childrens Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keith J. August</last_name>
      <phone>816-234-3265</phone>
    </contact>
    <investigator>
      <last_name>Keith J. August</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert J. Hayashi</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Robert J. Hayashi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Laura and Isaac Perlmutter Cancer Center at NYU Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teena Bhatla</last_name>
      <phone>212-263-4434</phone>
      <email>prmc.coordinator@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Teena Bhatla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bill H. Chang</last_name>
      <phone>503-494-1080</phone>
      <email>trials@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Bill H. Chang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Fox</last_name>
      <phone>215-590-2810</phone>
    </contact>
    <investigator>
      <last_name>Elizabeth Fox</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey E. Rubnitz</last_name>
      <phone>866-278-5833</phone>
      <email>info@stjude.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey E. Rubnitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern/Simmons Cancer Center-Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna S. Yi</last_name>
      <phone>713-798-1354</phone>
      <email>burton@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Joanna S. Yi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy C. Griffin</last_name>
      <phone>800-248-1199</phone>
    </contact>
    <investigator>
      <last_name>Timothy C. Griffin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas S. Hawkins</last_name>
      <phone>866-987-2000</phone>
    </contact>
    <investigator>
      <last_name>Douglas S. Hawkins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael J. Burke</last_name>
      <phone>414-805-4380</phone>
    </contact>
    <investigator>
      <last_name>Michael J. Burke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2015</study_first_submitted>
  <study_first_submitted_qc>December 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2015</study_first_posted>
  <last_update_submitted>June 21, 2017</last_update_submitted>
  <last_update_submitted_qc>June 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

